Guardant Health Management
Management criteria checks 4/4
Guardant Health's CEO is Helmy Eltoukhy, appointed in Jan 2013, has a tenure of 11.92 years. total yearly compensation is $11.59K, comprised of 0.01% salary and 100% bonuses, including company stock and options. directly owns 2.13% of the company’s shares, worth $83.40M. The average tenure of the management team and the board of directors is 3.6 years and 3.3 years respectively.
Key information
Helmy Eltoukhy
Chief executive officer
US$11.6k
Total compensation
| CEO salary percentage | 0.009% |
| CEO tenure | 11.9yrs |
| CEO ownership | 2.1% |
| Management average tenure | 3.6yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher
Nov 08
An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued
Oct 25Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Sep 24Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen
Aug 21Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce
Jul 31Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jul 12Guardant: Double-Digit Sales Projections Come At A Cost
Jun 06Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?
Jun 04Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%
May 14Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Mar 29With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For
Jan 21Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Nov 20Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Sep 26A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)
Sep 05Is Guardant Health (NASDAQ:GH) A Risky Investment?
Aug 15A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)
May 28Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Apr 05Is Guardant Health (NASDAQ:GH) Using Too Much Debt?
Dec 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$512m |
| Jun 30 2024 | n/a | n/a | -US$491m |
| Mar 31 2024 | n/a | n/a | -US$461m |
| Dec 31 2023 | US$12k | US$1 | -US$479m |
| Sep 30 2023 | n/a | n/a | -US$432m |
| Jun 30 2023 | n/a | n/a | -US$508m |
| Mar 31 2023 | n/a | n/a | -US$665m |
| Dec 31 2022 | US$12k | US$1 | -US$655m |
| Sep 30 2022 | n/a | n/a | -US$606m |
| Jun 30 2022 | n/a | n/a | -US$551m |
| Mar 31 2022 | n/a | n/a | -US$419m |
| Dec 31 2021 | US$14k | US$1 | -US$406m |
| Sep 30 2021 | n/a | n/a | -US$409m |
| Jun 30 2021 | n/a | n/a | -US$379m |
| Mar 31 2021 | n/a | n/a | -US$336m |
| Dec 31 2020 | US$114m | US$210k | -US$254m |
| Sep 30 2020 | n/a | n/a | -US$185m |
| Jun 30 2020 | n/a | n/a | -US$120m |
| Mar 31 2020 | n/a | n/a | -US$77m |
| Dec 31 2019 | US$915k | US$500k | -US$76m |
| Sep 30 2019 | n/a | n/a | -US$76m |
| Jun 30 2019 | n/a | n/a | -US$87m |
| Mar 31 2019 | n/a | n/a | -US$97m |
| Dec 31 2018 | US$818k | US$480k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$75m |
| Jun 30 2018 | n/a | n/a | -US$84m |
| Mar 31 2018 | n/a | n/a | -US$83m |
| Dec 31 2017 | US$4m | US$460k | -US$89m |
Compensation vs Market: Helmy's total compensation ($USD11.59K) is below average for companies of similar size in the US market ($USD6.65M).
Compensation vs Earnings: Helmy's compensation has been consistent with company performance over the past year.
CEO
Helmy Eltoukhy (45 yo)
11.9yrs
Tenure
US$11,591
Compensation
Dr. Helmy Eltoukhy, Ph D., is Partner of Green Sands Equity Incorporated. He is Equity Partner and Advisor of Transform VC.Dr. Eltoukhy has been the Chairman of the Board of Directors of Guardant Health,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.9yrs | US$11.59k | 2.13% $ 83.4m | |
| Co-CEO & Director | 3.3yrs | US$26.42k | 2.2% $ 86.3m | |
| Chief Financial Officer | 3.9yrs | US$4.12m | 0.021% $ 813.5k | |
| Chief Technology Officer | no data | US$4.76m | 0.044% $ 1.7m | |
| Chief Medical Officer | 3.6yrs | US$3.49m | 0.019% $ 758.7k | |
| Chief Commercial Officer | 3.5yrs | US$3.52m | 0.026% $ 1.0m | |
| Chief Information Officer | 4.9yrs | no data | 0.015% $ 583.0k | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 4.6yrs | US$6.02m | 0.027% $ 1.1m | |
| Senior Vice President of Public Affairs | no data | no data | no data | |
| Senior Vice President of Marketing | less than a year | no data | no data | |
| Chief People Officer | less than a year | no data | no data |
3.6yrs
Average Tenure
51yo
Average Age
Experienced Management: GH's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.9yrs | US$11.59k | 2.13% $ 83.4m | |
| Co-CEO & Director | 11.9yrs | US$26.42k | 2.2% $ 86.3m | |
| Independent Director | 3.2yrs | US$425.21k | 0.011% $ 434.7k | |
| Lead Independent Director | 7.9yrs | US$470.21k | 0.0068% $ 267.3k | |
| Director | less than a year | no data | no data | |
| Independent Director | 2.5yrs | US$425.21k | 0.0081% $ 318.9k | |
| Independent Director | 1.8yrs | US$725.30k | 0.0023% $ 88.8k | |
| Independent Director | 4.5yrs | US$425.21k | 0.014% $ 558.8k | |
| Independent Director | 3.3yrs | US$425.21k | 0.0062% $ 241.0k | |
| Director | less than a year | no data | no data |
3.3yrs
Average Tenure
50.5yo
Average Age
Experienced Board: GH's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 00:12 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guardant Health, Inc. is covered by 30 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |